David K. Shay

Active 1994–2025

104
Papers
27,498
Citations
81
h-index
103
i10-index

Citations

Citations per year for David K. Shay1981: 2 citations1989: 1 citations1995: 3 citations1996: 22 citations1997: 31 citations1998: 28 citations1999: 36 citations2000: 49 citations2001: 74 citations2002: 74 citations2003: 162 citations2004: 139 citations2005: 146 citations2006: 169 citations2007: 146 citations2008: 185 citations2009: 235 citations2010: 284 citations2011: 286 citations2012: 302 citations2013: 409 citations2014: 340 citations2015: 245 citations2016: 243 citations2017: 255 citations2018: 223 citations2019: 608 citations2020: 567 citations2021: 483 citations2022: 609 citations2023: 366 citations2024: 488 citations2025: 178 citations2026: 1 citations1982–1988: no citations, so these years are not shown1990–1994: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,217 citing papers, 35.6% of this breakdownUnited Kingdom: 588 citing papers, 6.5% of this breakdownCanada: 423 citing papers, 4.7% of this breakdownChina: 408 citing papers, 4.5% of this breakdownAustralia: 309 citing papers, 3.4% of this breakdownGermany: 253 citing papers, 2.8% of this breakdownItaly: 250 citing papers, 2.8% of this breakdownFrance: 243 citing papers, 2.7% of this breakdownNetherlands: 223 citing papers, 2.5% of this breakdownSpain: 191 citing papers, 2.1% of this breakdownJapan: 156 citing papers, 1.7% of this breakdownBelgium: 137 citing papers, 1.5% of this breakdown
0%35.6%Other 29.2%

Fields

  • Medicine80.2%
  • Immunology and Microbiology4.9%
  • Biochemistry, Genetics and Molecular Biology3%
  • Social Sciences2.8%
  • Mathematics2.3%
  • Health Professions1.5%
  • Other5.3%

Topics

  • Influenza Virus Research Studies13.9%
  • Respiratory viral infections research13.7%
  • Pneumonia and Respiratory Infections4.8%
  • SARS-CoV-2 and COVID-19 Research4.5%
  • Vaccine Coverage and Hesitancy3.3%
  • COVID-19 epidemiological studies2.8%
  • Other57%

Coauthors

All papers

Open in search
  1. Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States

    Authors: , , , , , , - JAMA 2003 cited by 3,703

  2. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2022 cited by 675

  3. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc‐Alain Widdowson - The Lancet Infectious Diseases 2012 cited by 1,372

  4. Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008

    Authors: , , , , , , , , , - Clinical Infectious Diseases 2012 cited by 584

  5. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe

    Authors: , , , , , , , , , , , , , - The Lancet Infectious Diseases 2022 cited by 183

  6. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , - MMWR Morbidity and Mortality Weekly Report 2022 cited by 150

  7. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States

    Authors: , , , , , , , , , , , , - JAMA Network Open 2023 cited by 81

  8. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2022 cited by 149

  9. Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , E.D. Collins, Mitesh Desai, Theresa M. Dulski, Barbara Dyleski, Kathryn M. Edwards, Melanie Feyereisen, Stephanie Gonsahn, Tchernavia Gregory, Jyothi Gunta, Kara Jacobs Slifka, Charlotte Kaboré, Bryan K. Kapella, Susan Karol, Kalah Kennebrew, Nancy Kluisza, Sean M. Lang, Labretta Lanier Gholston, Marcella Law, Jennifer Lehman, Jacek M. Mazurek, Henraya McGruder, Kiara McNamara, Maria-Luisa Moore, Pedro L. Moro, John F. Moroney, Oidda Museru, Cassandra Nale, Andi Neiman, Kimberly Newsome, Erika Odom, Brooke G. Pantazides, Suchita Patel, Agam K. Rao, Laura Reynolds, Sonya Robinson, Frederick L. Ruberg, Tammy Schaeffer, Dipesh Solanky, Laurence Sperling, Toscha Stanley, Regina M. Sullivan, Allan W. Taylor, Kimberly A. Thomas, Shayle Thompson, Jigsa Tola, Cuc H. Tran, Steven Wiersma, Kimberly Works - The Lancet Child & Adolescent Health 2022 cited by 78

  10. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP).

    Authors: , , , , , - 2011 cited by 762

  11. Estimates of US influenza‐associated deaths made using four different methods

    Authors: , , , , , , , - Influenza and Other Respiratory Viruses 2009 cited by 398

  12. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022

    Authors: , , , , , , , , , , - MMWR Morbidity and Mortality Weekly Report 2022 cited by 79

  13. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.

    Authors: , , , , , , , - 2009 cited by 1,974

  14. Influenza Vaccine Effectiveness in the 2011–2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates

    Authors: , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2013 cited by 346

  15. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US

    Authors: , , , , , , , , , - JAMA Network Open 2022 cited by 50

  16. Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024

    Authors: , , , , , , , , , , , , , , - MMWR Morbidity and Mortality Weekly Report 2024 cited by 35

  17. Influenza- and RSV-associated hospitalizations among adults

    Authors: , , , , , , , - Vaccine 2006 cited by 241

  18. The case test-negative design for studies of the effectiveness of influenza vaccine

    Authors: , , , - Vaccine 2013 cited by 285

  19. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011

    Authors: , , , , , , , , , - PLoS ONE 2013 cited by 213

  20. Risk Factors for Nipah Virus Infection among Abattoir Workers in Singapore

    Authors: , , , , , , , , , , , - The Journal of Infectious Diseases 2000 cited by 133

  21. COVID-19 Vaccination and Non–COVID-19 Mortality Risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021

    Authors: , , , , , , , , , , , , , , - MMWR Morbidity and Mortality Weekly Report 2021 cited by 127

  22. Influenza-Associated Deaths among Children in the United States, 2003–2004

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2005 cited by 653

  23. Effectiveness of Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine Strains

    Authors: , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2012 cited by 260

  24. Influenza Vaccine Effectiveness in the Community and the Household

    Authors: , , , , , , - Clinical Infectious Diseases 2013 cited by 192